-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Major Shareholder Holding Ltd Roche Sells 75,000 Shares
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Major Shareholder Holding Ltd Roche Sells 75,000 Shares
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Rating) major shareholder Holding Ltd Roche sold 75,000 shares of Jasper Therapeutics stock in a transaction dated Wednesday, January 25th. The shares were sold at an average price of $1.89, for a total transaction of $141,750.00. Following the completion of the transaction, the insider now directly owns 4,549,606 shares of the company's stock, valued at approximately $8,598,755.34. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Jasper Therapeutics Stock Down 2.7 %
JSPR stock traded down $0.05 during midday trading on Thursday, reaching $1.80. The company had a trading volume of 742,983 shares, compared to its average volume of 11,078,075. Jasper Therapeutics, Inc. has a 1-year low of $0.39 and a 1-year high of $5.81. The stock has a 50 day moving average price of $1.00 and a 200-day moving average price of $1.28.
Get Jasper Therapeutics alerts:Jasper Therapeutics (NASDAQ:JSPR – Get Rating) last issued its earnings results on Thursday, November 10th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. Sell-side analysts anticipate that Jasper Therapeutics, Inc. will post -1.34 EPS for the current fiscal year.
Analysts Set New Price Targets
Several research firms have commented on JSPR. Oppenheimer decreased their price objective on shares of Jasper Therapeutics from $21.00 to $8.00 and set an "outperform" rating on the stock in a report on Monday, November 14th. Credit Suisse Group decreased their price target on shares of Jasper Therapeutics from $7.00 to $3.00 and set an "outperform" rating on the stock in a research note on Wednesday, January 11th. Finally, EF Hutton Acquisition Co. I restated a "buy" rating and set a $4.00 price objective on shares of Jasper Therapeutics in a report on Wednesday, January 11th.Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC increased its holdings in Jasper Therapeutics by 3.8% in the 3rd quarter. Citadel Advisors LLC now owns 3,102,016 shares of the company's stock worth $2,448,000 after purchasing an additional 112,913 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Jasper Therapeutics by 10.3% in the third quarter. Vanguard Group Inc. now owns 530,120 shares of the company's stock valued at $418,000 after buying an additional 49,559 shares during the period. UBS Group AG boosted its position in Jasper Therapeutics by 3,294.6% during the 3rd quarter. UBS Group AG now owns 188,026 shares of the company's stock worth $148,000 after buying an additional 182,487 shares during the period. State Street Corp bought a new stake in Jasper Therapeutics during the 1st quarter worth approximately $77,000. Finally, Renaissance Technologies LLC bought a new position in shares of Jasper Therapeutics during the first quarter valued at $39,000. 68.37% of the stock is currently owned by institutional investors and hedge funds.
Jasper Therapeutics Company Profile
(Get Rating)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.
Featured Stories
- Get a free copy of the StockNews.com research report on Jasper Therapeutics (JSPR)
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- The Future Of E-Commerce: Analysis And New Data
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- Mullen Automotive: The Good News, The Bad And The Ugly Outlook
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Rating) major shareholder Holding Ltd Roche sold 75,000 shares of Jasper Therapeutics stock in a transaction dated Wednesday, January 25th. The shares were sold at an average price of $1.89, for a total transaction of $141,750.00. Following the completion of the transaction, the insider now directly owns 4,549,606 shares of the company's stock, valued at approximately $8,598,755.34. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
碧玉治療有限公司(NASDAQ:JSPR-獲取評級)主要股東控股有限公司羅氏在 1 月 25 日(星期三)的一項交易中出售了 75,000 股碧玉治療股票。股票以 1.89 美元的平均價格出售,總交易額為 141,750.00 美元。交易完成後,內幕人士現在直接擁有該公司股票的 4,549,606 股,價值約為 8,598,755.34 美元。該銷售在向 SEC 提交的文件中披露,該文件可通過以下方式獲得 證券交易所網站。擁有公司股票 10% 以上的主要股東必須披露其與 SEC 的交易。
Jasper Therapeutics Stock Down 2.7 %
碧玉治療股票下降 2.7%
JSPR stock traded down $0.05 during midday trading on Thursday, reaching $1.80. The company had a trading volume of 742,983 shares, compared to its average volume of 11,078,075. Jasper Therapeutics, Inc. has a 1-year low of $0.39 and a 1-year high of $5.81. The stock has a 50 day moving average price of $1.00 and a 200-day moving average price of $1.28.
JSPR 股票在周四中午交易期間下跌 0.05 美元,達到 1.80 美元。該公司的交易量為 742,983 股,相比其平均交易量為 11,078,075。碧玉治療有限公司的 1 年低點為 0.39 美元,為期 1 年的最高點為 5.81 美元。該股票的 50 日移動平均價為 1.00 美元,200 天移動平均價為 1.28 美元。
Jasper Therapeutics (NASDAQ:JSPR – Get Rating) last issued its earnings results on Thursday, November 10th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. Sell-side analysts anticipate that Jasper Therapeutics, Inc. will post -1.34 EPS for the current fiscal year.
賈斯珀治療(NASDAQ:JSPR-獲取評級)上次發布了 11 月 10 日(星期四)的盈利業績。該公司報告了本季每股盈利(0.32 美元),超過 0.03 美元的共識估計(0.35 美元)。賣方分析師預計,賈斯珀治療有限公司將在當前財政年度發布 -1.34 每股收益。
Analysts Set New Price Targets
分析師設定新的價格目標
Institutional Inflows and Outflows
機構流入和流出
Several institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC increased its holdings in Jasper Therapeutics by 3.8% in the 3rd quarter. Citadel Advisors LLC now owns 3,102,016 shares of the company's stock worth $2,448,000 after purchasing an additional 112,913 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Jasper Therapeutics by 10.3% in the third quarter. Vanguard Group Inc. now owns 530,120 shares of the company's stock valued at $418,000 after buying an additional 49,559 shares during the period. UBS Group AG boosted its position in Jasper Therapeutics by 3,294.6% during the 3rd quarter. UBS Group AG now owns 188,026 shares of the company's stock worth $148,000 after buying an additional 182,487 shares during the period. State Street Corp bought a new stake in Jasper Therapeutics during the 1st quarter worth approximately $77,000. Finally, Renaissance Technologies LLC bought a new position in shares of Jasper Therapeutics during the first quarter valued at $39,000. 68.37% of the stock is currently owned by institutional investors and hedge funds.
一些機構投資者最近修改了他們對該股票的持有量。城堡顧問有限責任公司在第三季度增加了其在賈斯珀治療的持有量 3.8%。城堡顧問有限責任公司現在擁有該公司股票 3,102,016 股價值 2,448,000 美元在上一個季度購買了 112,913 股股票後。先鋒集團股份有限公司在第三季度增加了 10.3% 的賈斯珀治療股份的股份。領航集團股份有限公司在期內額外購入 49,559 股股份後,擁有該公司股票價值 418,000 元的 530,120 股股份。瑞銀集團在第三季度將其在賈斯珀治療學的地位提高了 3,294.6%。瑞銀集團股份有限公司於期內額外購入 182,487 股股份後,擁有該公司股票價值 148,000 美元的 188,026 股股份。州街公司在第一季度購買了賈斯珀治療的新股份,價值約為 77,000 美元。最後,文藝復興技術有限責任公司在第一季度購買了賈斯珀治療股份的新頭寸,價值為 39,000 美元。68.37% 的股票目前由機構投資者和對沖基金擁有。
Jasper Therapeutics Company Profile
碧玉治療公司簡介
(Get Rating)
(取得評分)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.
Jasper Therapetics, Inc 是一家臨床階段生物技術公司,致力於開發用於造血幹細胞移植和基因療法的治療劑。它專注於調理劑和幹細胞工程的開發和商業化,以擴大幹細胞移植和前體內基因療法的使用,這種技術在移植前對細胞進行遺傳操作。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Jasper Therapeutics (JSPR)
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- The Future Of E-Commerce: Analysis And New Data
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- Mullen Automotive: The Good News, The Bad And The Ugly Outlook
- 獲取有關賈斯珀治療(JSPR)的研究報告的免費副本
- 雪佛龍以 750 億美元的股份回購令股東感到滿意
- 電子商務的未來:分析與新數據
- 列維·施特勞斯是一個非常適合收入投資者
- 3 個有大上升空間的小型大寫字母
- 馬倫汽車:好消息,壞的和醜陋的前景
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收賈斯珀治療日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收賈斯珀治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧